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A series of drugs have been reported to increase memory performance modulating
the dopaminergic system and herein modafinil was tested for its working memory
(WM) enhancing properties. Reuptake inhibition of dopamine, serotonin (SERT) and
norepinephrine (NET) by modafinil was tested. Sixty male Sprague–Dawley rats were
divided into six groups (modafinil-treated 1–5–10 mg/kg body weight, trained and
untrained and vehicle treated trained and untrained rats; daily injected intraperitoneally
for a period of 10 days) and tested in a radial arm maze (RAM), a paradigm for testing
spatial WM. Hippocampi were taken 6 h following the last day of training and complexes
containing the unphosphorylated or phosphorylated dopamine transporter (DAT-CC and
pDAT-CC) and complexes containing the D1–3 dopamine receptor subunits (D1–D3-
CC) were determined. Modafinil was binding to the DAT but insignificantly to SERT
or NET and dopamine reuptake was blocked specifically (IC50 = 11.11 µM; SERT
1547 µM; NET 182 µM). From day 8 (day 9 for 1 mg/kg body weight) modafinil was
decreasing WM errors (WMEs) in the RAM significantly and remarkably at all doses
tested as compared to the vehicle controls. WMEs were linked to the D2R-CC and the
pDAT-CC. pDAT and D1–D3-CC levels were modulated significantly and modafinil was
shown to enhance spatial WM in the rat in a well-documented paradigm at all the three
doses and dopamine reuptake inhibition with subsequent modulation of D1–3-CC is
proposed as a possible mechanism of action.
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Introduction
Cognitive enhancement (CE) is one of the major concerns as cognitive impairment is a hallmark
of aging and several brain disorders. Several drugs are available for the treatment of cognitive
impairment and modafinil 2-[(diphenylmethyl) sulfinyl] acetamide is one recommended and
prescribed recently for CE (Farah et al., 2004; Sofuoglu et al., 2013) due to relatively low adverse
effects (Hermant et al., 1991).
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Several studies have shown improved memory performance
in modafinil-treated rodents: Béracochea et al. (2001, 2003)
reported that modafinil (64 mg/kg) improves delay-dependent
working memory (WM) in mice and subsequently improvement
of WM in serial spatial discrimination reversal T-maze was
demonstrated. Modafinil also improved performance of spatial
memory in a Morris water maze (75 mg/kg) and fear memory
using contextual fear conditioning (0.75 mg/kg; Shuman et al.,
2009). Piérard et al. (2006) observed that modafinil led to optimal
WM performance in a T-maze at the dose of 8 mg/kg. Eagle et al.
(2007) revealed dose-dependent CE effects, i.e., rats performed
better in a stop-signal reaction time task at 3 and 10 mg/kg than
at doses of 30 or 100 mg/kg.
Cognitive enhancement effects of modafinil have been
studied extensively in human volunteers: modafinil improved
performance in short-term memory, WM, and inhibition control
in sleeping disorders (Scoriels et al., 2013). In attention deficit
hyperactivity disorder, modafinil exhibited positive effects on
short- and long-term memory (Turner et al., 2004a,b). Studies
using modafinil on memory deficits in schizophrenic patients
are quite promising and improvement of short-term verbal
memory, verbal WM performance, spatial WM errors (WMEs)
and strategy use is furthermore observed in schizophrenics
(Turner et al., 2004a,b; Scoriels et al., 2012). Minzenberg et al.
(2014) studied modafinil effects in schizophrenia and observed
improvement of rule selection and representation. Moreover,
modafinil was studied in healthy volunteers and significantly
enhanced performance in trials of cognition such as WM,
cognitive flexibility, and planning (Muller et al., 2004; Turner
et al., 2004a,b; Finke et al., 2010).
As to probable mechanisms of actions, modafinil binds
to the dopamine transporter (DAT) increasing synaptic
dopamine levels exciting dopaminergic and adrenergic
receptors resulting in wakefulness (Wisor, 2013). Following
modafinil administration hippocampal excitatory glutamatergic
neurotransmission increased and GABAergic neurotransmission
was decreased (Ferraro et al., 1997). Own previous results
indicated that GluA1 and GluA2-containing receptor complex
levels were increased in trained drug treated mice (Sase et al.,
2012).
Although there is vast evidence for involvement of the
dopaminergic system including receptors and DAT, there is
limited information on the assembly of DAT and pDAT, D1R,
D2R, and D3R-containing complexes (CC’s) but rather than on
transporter and receptor subunits.
It was therefore the aim of the study to show cognitive
enhancing effects of modafinil at three different doses and
hippocampal dopamine transporter and receptor complex levels
paralleling WMEs in the RAM and indeed, D2R and pDAT-CC’s
were linked to WM.
Materials and Methods
Synthesis of Modafinil
Modafinil was synthetized according to a published method
(Chatterjie et al., 2004; Rebiere et al., 2010).
Uptake and Release Assays
Dulbecco’s modified Eagle’s medium (DMEM) and trypsin
were purchased from PAA Laboratories GmbH (Pasching,
Austria). Fetal bovine serum was purchased from Invitrogen.
[3H] 5-HT ([3H] 5-hydroxytryptamine; [3H] serotonin;
28.3µCi/mmol) and [3H] DA ([3H]dihydroxyphenylethylamine,
[3H]dopamine; 46 µCi/mmol) were purchased from Perkin
Elmer, Boston, MA, USA. [3H]1-Methyl-4-phenylpyridinium
([3H]MPP+; 85 µCi/mmol) was supplied by American
Radiolabeled Chemicals (St. Louis, MO, USA). Paroxetine
was purchased from Santa Cruz Biotechnology, USA,
while mazindole and D-amphetamine were purchased from
Sigma–Aldrich Co.
For uptake experiments, the human isoforms of DAT, SERT,
andNETwere expressed in HEK293 (HEK-DAT, HEK-SERT, and
HEK-NET) cells. Modafinil-mediated monoamine transporter
effects on substrate uptake were analyzed as described previously
(Sucic et al., 2010). In brief, cells were grown in poly-d-lysine
(PDL) coated 96-well plates. Modafinil was dissolved in DMSO
and subsequently diluted in Krebs–Ringer–HEPES buffer (KHB;
25 mM HEPES.NaOH, pH 7.4, 120 mM NaCl, 5 mM KCl,
1.2 mM CaCl2, and 1.2 mM MgSO4 supplemented with 5 mM
D-glucose). To determine unspecific uptake in HEK-DAT and
HEK-NET 10 µM of mazindole were used while 10 µM of
paroxetine were used for HEK-SERT. The tritiated substrates
used to assess transport activity at HEK-DAT, HEK-SERT, and
HEK-NET, were 0.2 µM 3H-DA, 0.4 µM 3H-5HT, and 0.05 µM
3H-MPP+, respectively. Cells were washed once with KHB buffer
and incubated with compounds either 5 min for HEK-DAT and
HEK-SERT cells or 8 min for HEK-NET cells. Subsequently,
substrates were added and the reactions were stopped with ice-
cold KHB buffer after either 1 min for HEK-DAT andHEK-SERT
cells or 3 min for HEK-NET cells. Cells were lysed with 1% SDS
and released radioactivity was measured by a liquid scintillation
counter (Tri-carb-2300TR, Perkin Elmer). All the experiments
were repeated in triplicate.
The substrate/efflux experiments were performed as described
before (Sucic et al., 2010). Briefly, HEK-DAT cells were
grown in 5 mm diameter PDL-coated coverslips. Cells were
incubated with 0.1 µM 3H-MPP+ at 37◦C for 20 min. The
coverslips were transferred onto superfusion chambers (0.2 ml)
and excess radioactivity was washed out with KHB buffer
for 40 min (0.7 ml/min) at 25◦C to obtain stable baselines.
Thereafter, modafinil or D-amphetamine was added as depicted
in Figure 1 and the experiment was started with the collection
of fractions (2 min). During the experiments with enhanced
intracellular sodium concentration, the buffer was switched either
to monensin or remained at control buffer after the collection of
three baseline fractions for another five fractions. Subsequently,
modafinil or D-amphetamine was added for another five fractions
as indicated in Figure 1. Finally, the remaining radioactivity was
collected by treatment with 1% SDS.
Radial Arm Maze (RAM)
Animals
Male Sprague–Dawley rats, aged between 12 and 14 weeks, were
used in all experiments. They were bred and maintained in
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FIGURE 1 | Working memory error (WME) assessment of modafinil in
the radial maze for 10 days. Rats in groups of 10 and 5 mg/kg body
weight modafinil performed at a comparable level in the radial arm maze
(RAM) training up to day 7, but from day 8 trained drug animals performed
better as compared with their counterparts injected with vehicle whereas rats
in groups of 1 mg/kg body weight performed better on day 9 and 10. Data
analyzed using ANOVA and Bonferroni post hoc test. Data represented as
mean ± SD.
cages made of Makrolon and filled with autoclaved woodchips
in the Core Unit of Biomedical Research, Division of Laboratory
Animal Science and Genetics, Medical University of Vienna.
Food and water in bottles was available ad libitum. The
room was illuminated with artificial light at an intensity of
about 200 l× in 2 m from 5 am to 7 pm. Experiments
were carried out between 8 am and 2 pm All procedures
were carried out according to the guidelines of the Ethics
committee, Medical University of Vienna, and were approved
by Federal Ministry of Education, Science and Culture, Austria
(BMWFW-66.009/0114-WF/II/3b/2014). All efforts were made
to minimize animal suffering and to reduce the number of
animals used.
Sixty animals were injected intraperitoneally 1, 5, or 10 mg/kg
body weight modafinil dissolved in DMSO or DMSO as vehicle
and injected 30 min prior to training on each day and were
trained or untrained in the RAM. Low dose treatment for CE
was published previously (Eagle et al., 2007). The six groups were:
three different doses of modafinil (1, 5, and 10 mg/kg) for trained
group, one 10 mg/kg modafinil untrained group and two vehicle
trained and untrained group. Animals in the vehicle group were
injected with DMSO at a dose of 1 ml/kg of body weight (Bartsch
et al., 1976).
Apparatus
The maze was made out of black plastic and kept at an elevation
of 80 cm above the floor in a room with numerous visual cues.
The central platform had a diameter of 50 cm with 12 arms
(12 cm × 60 cm) projecting radially outward. A plastic cylinder
was used to restrict the movement of rats in the center before the
start of training. Lifting of the cylinder was controlled by a pulley
system from the far end of the room.
Procedure
Radial arm maze training was performed as described in
Levin et al. (2010) and Timofeeva et al. (2010) with some
modification. In brief: rats were handled for 5 days for adaptation
(30 min/day/rat) and also to reduce the body weight to 85%.
Water was provided ad libitum during the training. The amount
of food (ssniff Spezialdiäten GmbH) was provided to maintain
a lean, healthy body weight of approximately 85% of the free-
feeding weight during training. Out of 12 arms, eight arms were
baited with a small piece (40mg) of same food during the training
and four remained un-baited. Before the start of the training,
rats were given two habituation sessions in which food was
placed all over the maze and rats were allowed to explore the
maze and eat the food for 5 min. During the training session,
the same arms were baited for each rat once at the beginning
of each session to assess WM, while the other four arms were
always left un-baited in order to test reference memory. The
pattern of baited and un-baited arms were consistent throughout
testing for each rat but differed among rats. Each trial started
by placing the rat onto the central platform, after 10 s the
cylinder was lifted slowly and the rat was allowed to enter any
arm. The session lasted 8 min or until all eight baited arms
were entered-whatever occurred first. The maze was cleaned
between the two trials by using 1% incidin (Ecolab GmbH,
Austria). Arms were baited only once and a repeated entry into
a baited arm was counted as a WME, whereas any entry into
an un-baited arm was recorded as a reference memory error.
The rats were given 10 training sessions, one training per day.
Untrained group rats underwent similar handling, habituation,
food restriction, and spent the same time in the RAM as their
counterpart trained group rats except there was no food during
the trials so that they do not form any memory. The training
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sessions were recorded with a computerized tracking video
camcorder: 1/3 SSAM HR EX VIEW HAD. Six hours after the
end of the tenth training animals were deeply anesthetized with
CO2 and killed by neck dislocation. Brain tissues were quickly
removed and hippocampi were rapidly dissected on a cold
plate set at 4–6◦C and stored at –80◦C till further biochemical
analysis.
Blue Native-Polyacrylamide Gel
Electrophoresis (BN-PAGE)
Only the 10 mg/kg body weight dose group was used for
proteomic studies. Ten whole hippocampi from each of the
four groups were run on BN-PAGE followed by immunoblotting
with antibodies against the DA receptor and transporter systems,
namely D1R, D2R, D3R, pDAT, and DAT.
Homogenization, Sample Preparation and Extraction
of Membrane Proteins
All procedures were performed at 4◦C as published previously
(Saroja et al., 2014). The extracted membrane receptor proteins
were then aliquoted and stored at −80◦C until use. The extracted
fractions were used for BN-PAGE.
Blue Native-Polyacrylamide Gel Electrophoresis
Membrane pellets from the ultracentrifugation fraction were
solubilized in extraction buffer (1.5 M 6-aminocaproic acid,
300 mM Bis–Tris, pH 7.0) and 10% Triton X-100 (stock
solution was added at a ratio of 1:4 to achieve final 2% Triton
X-100 concentration) with vortexing every 10 min for 1 h.
Following solubilization, samples were cleared by centrifugation
at 20,000 × g for 60 min at 4◦C. The protein content was
estimated using the BCA protein assay kit (Pierce, Rockford, IL,
USA). Seventy microgram of the membrane protein preparation
were applied onto gels. 16 mL of BN-PAGE loading buffer [5%
(w/v) Coomassie G250 in 750 mM 6-aminocaproic acid] were
mixed with 100 µL of the membrane protein preparation and
loaded onto the gel. BN-PAGE was performed in a PROTEAN
II xi Cell (Bio-Rad, Germany) using 4% stacking and 5–13%
separating gel. The BN-PAGE gel buffer contained 500 mM
6-aminocaproic acid, 50 mM Bis–Tris, pH 7.0; the cathode
buffer 50 mM Tricine, 15 mM Bis–Tris, 0.05% (w/v) Coomassie
G250, pH 7.0 and the anode buffer 50 mM Bis–Tris, pH 7.0.
The voltage was set to 50 V for 1 h, 75 V for 6 h, and was
increased sequentially to 400 V (maximum current 15 mA/gel,
maximum voltage 500 V) until the dye front reached the
bottom of the gel (Kang et al., 2008). Native high molecular
mass markers were obtained from Invitrogen (Carlsbad, CA,
USA).
Immunoblotting
Membrane proteins were transferred from BN-PAGE to PVDF
membranes. After blocking of membranes for 1 h with 10 % non-
fat drymilk in 0.1%TBST (100mMTris–HCL, 150mMNaCl, pH
7.5, 0.1% Tween 20), membranes were incubated with primary
antibodies D1R (diluted 1:5000, Abcam-ab78021, Cambridge,
UK ), D2R (diluted 1:5000, Abcam-ab21218, Cambridge, UK),
D3R (diluted 1:5000, Abcam- ab42114, Cambridge, UK), pDAT
(diluted 1:5000, DAT Thr53, Phosphosolutions-p435-53, Aurora,
United States) and DAT (diluted 1:5000, Abcam- ab111468,
Cambridge, UK) and detected with horseradish peroxidase-
conjugated anti-rabbit IgG (diluted 1:10000, Abcam- ab6721,
Cambridge, UK). Membranes were developed with the Bio-Rad
ClarityTM Western ECL Substrate. Arbitrary optical densities of
immunoreactive bands were measured by the Image J software
program1. After developing, total protein staining was done on
PVDF membranes as previously described for loading control.
Radio Ligand-Binding Assay
Sample Preparation
Hipocampi and cerebral cortices of rats were homogenized in
ice cold 50 mM Tris-HCl (pH 7.4–7.5) in a glass/Teflon Potter
homogenizer. Suspensions were diluted to 100 times the tissue
volume in 35 ml centrifuge tubes and EDTA was added to the
final concentration of 3 mM. The homogenates were centrifuged
for 10min at 35000× g. The resultant pellets were resuspended in
same ice cold buffer and centrifuged again. The obtained pellets
were resuspended again and incubated for 2 h in a 23◦C water
bath subsequently followed by a third centrifugation. Membranes
were stored as 50 mg aliquots at −80◦C until use.
[3H]SCH 23390 and [3H]Raclopride Binding Assay
In order to test the binding potential of modafinil on D1R and
D2R the actual dissociation constants of [3H]SCH 23390 and
[3H]Raclopride (American Radiolabeled Chemicals Inc.) were
determined as published previously (Dewar et al., 1989; Sun
et al., 2012). All stock solutions of drugs and radioligands were
prepared in a buffer (120 mM NaCl; 50 mM Tris-HCl; 5 mM
KCl; pH 7.4–7.5) at room temperature. [3H]SCH 23390 and
[3H]Raclopride ligands (70–90 Ci/mMol) were evaporized to
remove ethanol and 20 nM stocks were prepared. Membrane
preparations obtained were prewashed by centrifuging at
35000 × g (Sorvall, rotor SS 34) for 10 min at room
temperature with a buffer (120 mM NaCl; 50 mM Tris-HCl;
5 mM KCl; pH 7.4–7.5). All experiments were carried out in
triplicates.
For D1R, membrane preparations were incubated in a buffer
(120 mM NaCl; 50 mM Tris-HCl; 5 mM KCl; pH 7.4–7.5)
with the addition of 2 nM of [3H] SCH 23390 and 30 nM
Ketanserin (Janssen Pharmaceutica, Beerse, Belgium) in water
bath at 23◦C for 1 h; while for D2R, membrane preparations
were incubated in buffer with 2 nM [3H]Raclopride in water
bath at 23◦C for 1 h. Non-specific binding was determined
by adding 10 µM Butaclamol (Ayerst Laboratories, Montreal,
QC, Canada) to the incubation. Five concentrations (0,1 nM–
300 nM) of non-labeled SCH 23390 (Schering Corp., Bloomfield,
NJ, USA) and Raclopride (Sigma–Aldrich–Chemie GmbH,
Seinheim, Germany) were used to construct a saturation curve.
Filtration
Membranes with bound radioligand were collected after dilution
with buffer, with Brandel harvester on glass fiber filters (GF-
B or GF-C) pre-soaked in 0.3% polyethylenimine. They were
1http://imagej.nih.gov/ij/
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FIGURE 2 | RME assessment of modafinil in the radial maze for 10 days. RME’s did not change significantly because of vehicle or modafinil treatment
[F (3,360) = 0.6625, p = 0.5756] or training [F (9,360) = 1.658, p = 0.0977]. Bonferroni post hoc analysis comparing vehicle group with modafinil treated groups at
different time points showed no significant changes. Data represented as mean ± SD.
washed three times with buffer and the filters were transferred to
picovials. After addition of 1.8 ml toluene scintillation cocktail
(50 g PPO and 5 g POPOP dissolved in 10 L toluene), vials
were left for 20 min shaking. Radioactivity was counted in the
betacounter (Tri-Carb 2100TR, Packard).
Statistics
Non-linear regression analysis was carried out for reuptake assays
to determine the IC50 values.
During the training phase, repeated measurement two way
ANOVA with the factors, treatment and the training were used.
A pairwise multiple comparison was done using the Bonferroni
post hoc test. Pearson correlation was used for correlation
analysis between receptor/transporter complex levels and the
WMEs.
For BN-PAGE, densitometry analysis was performed to
quantify the level of the receptors and transporters in all four
groups. One way ANOVA and Bonferroni post hoc analysis was
performed to reveal differences. All values were expressed as
mean ± SD and the probability level of p < 0.05 was considered
as statistically significant.
All calculations were performed using GraphPad Prism
version 6.00 for Windows, GraphPad Software2, San Diego, CA,
USA.
For radio ligand-binding assay, dissociation constants KD
and maximal number of binding sites BM were estimated by
adding five concentrations of unlabeled ligand (SCH 23390
and Raclopride, respectively) and calculating the amount
specifically bound ([3H]ligand + [1H]ligand). Specifically
bound ligand was plotted against the ratio ‘bound over free’
(Eadie–Hofstee plot) and the parameters KD (negative slope)
2www.graphpad.com
and BM (intercept with ordinate) were evaluated by linear
correlation.
Results
Radial Arm Maze
As shown in Figures 1–3 and Supplementary Tables S1–S3 the
animals learned the task and WMEs were gradually decreasing,
F(9,360) = 17.09, p < 0.0001. In the 1 mg/kg body weight
dosage group reduction of WME became significant on day 9
while animals administered 5 and 10 mg/kg body weight showed
significant reduction of WMEs from day 8, F(3,360) = 3.959,
p = 0.0085. RME’s did not change significantly because of
vehicle or modafinil treatment [F(3,360) = 0.6625, p = 0.5756]
or training [F(9,360) = 1.658, p = 0.0977]. But there was
significant difference in the latency’s over the training days
[F(9,360) = 28.65, p < 0.0001] and treatment [F(3,360) = 18.79,
p < 0.0001]. Bonferroni post hoc analysis comparing vehicle
group with modafinil treated groups at different time points
showed significant changes.
Reuptake Inhibition and Release/Efflux Assays
A substrate inhibition assay was performed using HEK293
cells, stably expressing DAT, SERT, and NET. IC50 values
of modafinil on DAT, SERT, and NET were 11.11 µM,
1547 µM, and 182.3 µM, respectively (Figure 4A) suggesting
that modafinil rather selectively targets DAT-mediated dopamine
uptake as compared to SERT and NET. Subsequently release
or efflux assays were performed to examine whether modafinil
behaves as a blocker or substrate of DAT. Ten µM of
modafinil were used for the release assay, while 10 µM of
D-amphetamine served as a positive control, in the presence
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FIGURE 3 | Latency assessment of modafinil in the radial maze for 10 days. Latency was significantly different over the training days [F (9,360) = 28.65,
p < 0.0001] and treatment [F (3,360) = 18.79, p < 0.0001]. Data analyzed using ANOVA and Bonferroni post hoc test. Data represented as mean ± SD.
FIGURE 4 | Substrate inhibition and release assays of modafinil.
(A) For uptake experiments, HEK-DAT, HEK-SERT, and HEK-NET cells
were incubated with increasing concentrations of modafinil for 5 min.
Subsequently, tritiated substrates were added and the experiments were
performed as described in the Section “Materials and Methods.” Unspecific
uptake was determined by using 10 µM of mazindole for HEK-DAT and
HEK-NET and 10 µM of paroxetine for HEK-SERT. The percentage of
maximum uptake was obtained without adding any inhibitory substances.
(B) The release assay was performed in HEK-DAT cells. Cells were grown
on PDL coated coverslips, treated with 0.1 µM 3H-MPP+ at 37◦C for
20 min and washed with KHB buffer for 40 min at superfusion chambers.
First three (baseline) and next five fractions were without any compounds
and with 25 µM monensin, respectively. Final five fractions were with either
10 µM modafinil or 10 µM amphetamine. Non-linear regression analysis
was carried out by using Graphpad prism 6. Values are given as
mean ± SEM.
of 25 µM monensin. DAT-mediated substrate release was
not affected by modafinil, indicating that modafinil selectively
blocks DAT-mediated uptake, without acting as a substrate
(Figure 4B).
Results from BN Followed by Immunoblotting
In the 10 mg/kg body weight dosage group, hippocampal DA
receptor and transporter complexes were separated by BN-
PAGE following immunoblotting (Figure 5A) and levels were
quantified by densitometry analysis. Equal loading was checked
by Coomassie R-350 of PVDFmembranes as described in Section
“Materials and Methods.”
As shown in Figure 5B, levels of D1R-CC were increased
in both, untrained drug and trained drug in comparison to
untrained vehicle, proposing drug effects. D1R-CC levels in
trained vehicle showed no significant difference in comparison
to untrained vehicle but in trained drug there was an increase in
comparison to trained vehicle.
As indicated in Figure 5C, D2R-CC levels were decreased
in trained vehicle in comparison to untrained vehicle
pointing to an effect of WM performance while a trend to
decreased levels was observed in trained drug. Untrained
drug showed no remarkable differences to untrained
vehicle. D2R-CC levels in trained vehicle were decreased in
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FIGURE 5 | Representative BN-PAGE western blot images and graphical
presentation of D1R, D2R, D3R, DAT, and pDAT levels in untrained drug,
trained drug, untrained vehicle and trained vehicle groups. Total
hippocampal membrane fractions were run on 5–13% gradient BN-PAGE gel
and blotted onto PVDF membranes. Immunoreactivity of protein CC’s were
observed with respective antibodies. Intensity of optical densities of D1R-CC,
D2R-CC, D3R-CC, DAT-CC, pDAT-CC were normalized against optical density
of the entire corresponding lanes on the membrane. (A) Representative images
of three bands for dopamine receptor or transporter CC. Approximate molecular
weights are indicated; Graphical presentation of receptor and transporters CC
levels that were compared are shown as (B) D1R (n = 10), (C) D2R (n = 10),
(D) D3R (n = 10), (E) DAT (n = 10), (F) pDAT (n = 10). Statistical evaluation was
carried out by one way ANOVA followed by post hoc Bonferroni test. Data is
provided as mean ± SD. (∗p < 0.05;∗∗p ≤ 0.01).
comparison to untrained drug proposing a WM training
effect.
D3R-CC levels as demonstrated in Figure 5D showed
decreased levels in trained drug and trained vehicle as compared
with untrained vehicle indicating a WM and drug effect, while a
trend to decreased levels was seen in untrained drug.
As shown in Figures 5E,F, DAT-CC levels were comparable
across groups whereas pDAT-CC levels were increased in
untrained drug in comparison with untrained vehicle proposing
a drug effect. Trained drug and trained vehicle showed no
significant differences to untrained vehicle but trained vehicle was
decreased in comparison to untrained drug pointing to a drug
effect.
The representative loading control and additional
representative full blot is provided in Supplementary Figures S1
and S2.
Correlations between pDAT, D2R-CC, and
WME
The Pearson correlation was calculated to evaluate the
relationship between receptor/transporter complex levels
and the WMEs on the last day of the training.
As shown in Figures 6A,B, D2R-CC levels were positively
correlating with WME of trained vehicle (r = 0.73; p = 0.04)
in the RAM whereas levels of pDAT-CC’s were negatively
correlating with WME of trained drug (r = −0.677;
p = 0.03).
Moreover, in trained drug, as indicated in Figures 6C–F,
D1R-CC and D3R-CC (r = 0.79; p = 0.006); DAT-CC and D1R-
CC (r = 0.8218; p = 0.003); D2R-CC and D3R-CC (r = 0.63;
p= 0.04); DAT-CC and D3R-CC (r = 0.87; p= 0.0008) showed a
positive correlation probably indicating a network or functional
interactome of dopamine receptors.
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Radioligand Binding Assay
Since in the BN-PAGE Western blotting, changes of D1-like
and D2-like dopamine receptors in the hippocampus after
prolonged treatment of rats with modafinil were observed, it
was decided to show whether the drug accomplished these
effects by direct interaction with these receptors. To our
knowledge, modafinil effects have never been tested on these
receptors in rat hippocampal tissue, most likely due to their
very low densities in that brain region. In pilot experiments
(Supplementary Table S4), D1-like receptors at fair densities in
the cerebral cortex and hippocampus were observed. However,
much lower levels of D2-like receptors were found in these
regions. While in the cerebral cortex, saturable [3H]raclopride
binding could be resolved, saturation analysis did not result in
reliable parameters in hippocampal tissue. Binding of neither of
the two radioligands was inhibited to any significant extent by
the highest concentration of modafinil (Von Huben et al., 2006)
applied.
Discussion
The major finding of the current study is represented by CE of
Sprague–Dawley rats in the RAM by three low or moderate doses
of modafinil. Moreover, D2R-CC as well as the phosphorylated-
CC, i.e., activated form of the DAT were linked to WMEs.
In contrast to DAT-CC levels, changes of pDAT, D1R, D2R,
and D3R-CC were paralleling CE in the RAM by modafinil.
D1R, D2R, and D3R have been already shown to be linked to
WM:
D1R antagonism is modulating and linked to WM
(Sawaguchi and Goldman-Rakic, 1991, 1994; Von Huben
et al., 2006; Beaulieu and Gainetdinov, 2011; Clausen et al.,
2011) Furthermore, blocking hippocampal D1 class receptors
during learning impaired one trial place memory (Brozoski et al.,
1979), and D1R is critically modifying performance accuracy
in several WM tasks (Cai and Arnsten, 1997; Henze et al.,
2000; Gonzalez-Burgos et al., 2005; Kobori and Dash, 2006;
FIGURE 6 | Correlation analysis data. The Pearson correlation analysis was
calculated to evaluate the link between receptor/transporter CC levels and the
WMEs on the last day of training. (A) The D2R-CC levels positively correlated
with WME’s in the trained vehicle group (r = 0.73; p = 0.04); (B) p-DAT-CC
levels negatively correlated with WMEs in the trained drug group (r = −0.67;
p = 0.03); Correlation amongst receptor/receptor and receptor/transporter CC
levels was also analyzed by Pearson correlation analysis as (C) D3R and D1R in
the trained drug group showed a positive correlation (r = 0.79; p = 0.006);
(D) DAT and D1R in the trained drug group showed a positive correlation
(r = 0.82; p = 0.003); (E) D3R and D2R in the trained drug group showed a
positive correlation (r = 0.63; p = 0.04); (F) DAT and D3R in the trained drug
group showed a positive correlation (r = 0.87; p = 0.0008).
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Amico et al., 2007). Finally, the use of previously acquired spatial
information in a RAM required D1R activation (Seamans et al.,
1998).
In the current study a drug effect by modafinil was observed,
however, neither a training effect nor a correlation between D1R-
CCs with WMEs was observed. This is not a contradiction, as the
current study was carried out determining D1R-CC’s rather than
D1R subunits.
D2R-CC’s herein were shown to be reduced by training in
the RAM in trained vehicle animals although this was observed
as a trend only in trained drug animals. There was, however,
a significant positive correlation between D2R-CC’s and WMEs
proposing a link between WM and D2R-CC in vehicle-treated
rats. And indeed, involvement of the D2R in WM was already
suggested (Luciana et al., 1992; Kimberg et al., 1997, 2001; Muller
et al., 1998; Mehta et al., 2004): D2R antagonism leading to WM
enhancement is consistent with our own observation herein.
As to the D3R, antagonism counteracts cognitive impairment
in several rodent and primate procedures including WM (Millan
et al., 2010) and Xing et al. (2012) reported that D3R in contrast
to D1R does not play a fundamental role in spatial WM.
Herein, training in the RAM reduced D3R-CC’s in vehicle
treated animals. This receptor complex correlated with D1R,
D2R and DA-CC’s pointing to cooperativity between these
dopaminergic systems inWM although no significant correlation
between D3R-CC and WMEs was observed.
The DAT-CC levels were comparable between groups, the
pDAT-CC levels, however, were reflecting a drug effect. pDAT-
CC levels were strongly and negatively correlated with WMEs
compatible with a link between this activated DAT form and
the WMEs in trained, modafinil-treated rats. Although no
significant correlation between DATs and D2R-CC was observed,
literature reveals a physical and functional interaction among
them (Bowton et al., 2010). This may well indicate that the bands
immunoreactive for DAT-CC levels observed in BN-PAGE-WB
herein may contain D2R-CC and correlations between DAT-
CC, D1R-CC, and D3CC may at least suggest functional if
not physical interaction. In addition, other neurotransmitter
receptors may be contained in the observed complexes The goal
of the study was to identify and quantify D1R, D2R, D3R, DAT-
, and pDAT-CC levels and we are aware of the fact that in
the observed bands a vast series of individual receptors may be
contained (Liu et al., 2006; So et al., 2009; Borroto-Escuela et al.,
2014; Fuxe et al., 2014a,b; Khan and Lee, 2014; Kivell et al.,
2014).
A putative mechanism of CE in the RAM by modafinil
dopamine reuptake inhibition (Elliott et al., 1997; Nail-Boucherie
et al., 1998; Mattay et al., 2003; Gerrard and Malcolm, 2007;
So et al., 2009) followed by modulation of dopamine receptors
may be proposed and a direct effect of modafinil on dopamine
receptor complexes was ruled out.
Supplementary Material
The Supplementary Material for this article can be found
online at: http://journal.frontiersin.org/article/10.3389/fnbeh.
2015.00215
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